Product Description: Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research[1][2][3][4][5].
Applications: COVID-19-immunoregulation
Formula: C22H22FN7O2
References: [1]Roedder S, et, al. Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects. 2021 Nov 6./[2]WHO Drug Information. International Nonproprietary Names for Pharmaceutical/[3]Feng Y, et al. Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer[J]. Acta Pharmaceutica Sinica B, 2024./[4]Kurochkina Y, et al. POS0673 TOLEROGENIC DENDRITIC CELLS IN RHEUMATOID ARTHRITIS PATIENTS: NEWS AND PROMISES[J]. 2021./[5]Kalliolias GD, et al. Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update. Biomedicines. 2024 Jan 9;12(1):138.
CAS Number: 2408839-73-4
Molecular Weight: 435.45
Compound Purity: 99.86
Research Area: Inflammation/Immunology
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: IRAK
Deutsch
English
